drugset / Trial / NCT03407105
A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of 2 or 4 doses of MDX-010 in HIV-infected subjects
Timeline
- Start
- 2003-04-21
- Primary completion
- 2006-02-21
- Completion
- 2006-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 0.1 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 5 mg/kg | — |